A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
AstraZeneca
BeiGene
M.D. Anderson Cancer Center
Checkpoint Therapeutics, Inc.
Phanes Therapeutics
Deciphera Pharmaceuticals, LLC
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
SCRI Development Innovations, LLC
Canadian Cancer Trials Group
Nektar Therapeutics
iOMEDICO AG
NextCure, Inc.
AbbVie
AbbVie
Mereo BioPharma
AstraZeneca
AbbVie
M.D. Anderson Cancer Center
Institut Cancerologie de l'Ouest
AstraZeneca
AbbVie
Amgen